Swisschems sells Semaglutide and Retatrutide as unapproved new drugs despite research-chemical labeling.
What happened
FDA reviewed the Swisschems website in October 2024 and the company’s Facebook and Instagram pages. It found Semaglutide and Retatrutide offered for sale in the U.S., with claims that FDA said showed the products were intended as drugs for human use despite “research chemicals only” labeling. FDA said no approved applications were in effect for the products.
What FDA found
Swisschems offered Semaglutide for sale without an FDA-approved application.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)Swisschems offered Retatrutide for sale without an FDA-approved application.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)Website and social media claims made clear the products were intended as drugs for human use, despite “research chemicals only” labeling.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)FDA treated the products as new drugs not generally recognized as safe and effective for the claimed uses.
FD&C Act section 201(p), 21 U.S.C. 321(p)No approved applications were in effect for these products.
FD&C Act section 505, 21 U.S.C. 355
What FDA wants
FDA tells Swisschems to notify it in writing within fifteen working days of the specific steps taken to correct the violations and prevent recurrence, with supporting documentation. If corrective action cannot be completed in that time, the company must state why and give a completion date.
Who should pay attention
- companies selling research chemicals online
- brands marketing GLP-1 or weight-loss products
- quality teams reviewing online product claims
This is a summary. Read the original letter on fda.gov.